Resources for You
Caprelsa (vandetanib) Tablets
Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – October 2012
Clinical Studies Experience
- Table 1 - Adverse Reactions With a ≥ 5% Increased Incidence in Patients on Caprelsa Compared to Placebo During Randomized Treatment: Updated and additions made.